The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Lurasidone (Latuda) for Schizophrenia

The FDA has approved lurasidone (Latuda – Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.

DRUGS FOR SCHIZOPHRENIA — Controlled trials have failed to demonstrate greater efficacy with the second-generation antipsychotics shown in Table 2 compared to less expensive first-generation drugs such as haloperidol (Haldol, and others), except for clozapine, which requires monitoring to prevent life-threatening adverse effects, and possibly olanzapine, which has substantial adverse metabolic effects.1 The second-generation antipsychotics do have a relatively low risk of extrapyramidal symptoms, and are probably less likely than first-generation antipsychotics to cause tardive dyskinesia.2

CLINICAL STUDIES — Four 6-week, fixed-dose placebo-controlled trials ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1358
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian